Achieve Life Sciences Closes Merger with OncoGenex

Longevity Investing

Achieve Life Sciences completed its merger with OncoGenex Pharmaceuticals.

Achieve Life Sciences (NASDAQ:ACHV) completed its merger with OncoGenex Pharmaceuticals.
As quoted in the press release:

As a result of which the stockholders of Achieve have become the majority stockholders of OncoGenex. OncoGenex has been renamed Achieve Life Sciences and the operations and employees of OncoGenex and Achieve have combined to carry on as a fully-integrated late-stage smoking cessation company.
Achieve Life Sciences will continue to be headquartered in Bothell, WA with its existing operations in Vancouver, B.C, and is focused on the clinical and commercial development of cytisine, a selective nicotine receptor partial agonist currently in late-stage development for smoking cessation.
“Cytisine is a drug of global public health importance and the transition of Achieve to the public markets is a critical step in advancing our development program,” commented Rick Stewart, Chairman and CEO of Achieve Life Science. “With our combined resources and the extraordinary level of collaboration between the teams, we believe we are now well-positioned to execute our plans to bring forward a new treatment option for people battling nicotine addiction.”

Click here to read the full press release.

Source: www.newswire.ca

The Conversation (0)
×